Role of Pharmacogenomics in Predicting and Preventing Adverse Drug Reactions: A Systematic Review of Gene–Drug Interactions and Clinical Outcomes

Pharmacotherapy is an essential component of modern healthcare. However, individuals receiving the same medication and dosage may experience different therapeutic responses. Some patients achieve the desired therapeutic effect, while others develop adverse drug reactions or experience inadequate treatment outcomes.

Adverse drug reactions are unintended and harmful responses associated with the use of medicines. They represent an important public health concern because they may increase morbidity, hospitalization and healthcare expenditure.

Several factors contribute to individual variations in drug response, including age, gender, body weight, organ function, environmental factors, drug interactions and genetic differences.

Pharmacogenomics is the study of how variations in an individual's genetic makeup influence drug response. Genetic polymorphisms affecting drug-metabolizing enzymes, drug transporters and pharmacological targets may alter drug concentration, efficacy and toxicity.

For example:

- CYP2C19 genetic variations can influence clopidogrel activation and antiplatelet response.

- CYP2D6 variations can influence the metabolism of codeine and other medications.

- HLA-B*15:02 is associated with an increased risk of carbamazepine-induced severe cutaneous adverse reactions.

- TPMT and NUDT15 variations can influence thiopurine-related toxicity.

Pharmacogenomic testing can help identify patients who may benefit from alternative medications or adjusted doses. Clinical resources such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) provide recommendations for translating genetic test results into prescribing decisions.

Therefore, evaluating the relationship between genetic variations and adverse drug reactions is important for developing safer and more individualized treatment strategies.

2. AIM AND OBJECTIVES

2.1 Aim

To evaluate the role of pharmacogenomics in predicting and preventing adverse drug reactions through a systematic review of published scientific literature.

2.2 Objectives

1. To identify important genetic polymorphisms associated with adverse drug reactions.

2. To evaluate clinically significant gene–drug interactions.

3. To investigate the role of pharmacogenomic testing in predicting medication-related toxicity.

4. To assess the effectiveness of genotype-guided prescribing in reducing adverse drug reactions.

5. To identify barriers to implementing pharmacogenomics in routine clinical practice.

3. REVIEW OF LITERATURE

3.1 Pharmacogenomics and Drug Metabolism

Genetic variations in drug-metabolizing enzymes can influence the absorption, distribution, metabolism and elimination of medications.

The cytochrome P450 enzyme family plays an important role in the metabolism of many commonly prescribed drugs.

Variations in CYP2D6, CYP2C19 and CYP2C9 may result in different metabolizer phenotypes, potentially influencing drug efficacy and toxicity.

3.2 Important Gene–Drug Interactions

Some clinically important examples include:

Gene| Drug| Clinical relevance

CYP2C19| Clopidogrel| Reduced activation and antiplatelet response

CYP2D6| Codeine| Altered morphine formation and toxicity risk

HLA-B*15:02| Carbamazepine| Severe cutaneous adverse reaction risk

TPMT| Azathioprine| Increased risk of myelosuppression

NUDT15| Thiopurines| Increased risk of myelotoxicity

DPYD| Fluoropyrimidines| Increased risk of severe toxicity

3.3 Pharmacogenomics in Personalized Medicine

Pharmacogenomic testing helps identify genetic variations that may influence medication response.

Based on the test results, healthcare professionals may consider changing the drug, adjusting the dosage or selecting an alternative treatment.

3.4 Clinical Implementation

Although pharmacogenomic testing has demonstrated clinical utility for selected gene–drug pairs, its widespread implementation remains challenging.

Important barriers include testing costs, limited availability, lack of awareness, interpretation difficulties and differences in genetic variant frequencies across populations.

MATERIALS AND METHODS

4.1 Study Design

A systematic review of published scientific literature will be conducted following PRISMA 2020 reporting guidelines.

4.2 Literature Search Strategy

The following electronic databases will be searched:

1. PubMed/MEDLINE

2. Google Scholar

3. Cochrane Library

4. Scopus, if accessible

4.3 Search Keywords

- Pharmacogenomics

- Pharmacogenetics

- Adverse drug reactions

- Genetic polymorphism

- Drug toxicity

- Gene–drug interaction

- Personalized medicine

- Genotype-guided prescribing

4.4 Inclusion Criteria

1. Original research articles and relevant clinical studies.

2. Studies investigating pharmacogenomic associations with adverse drug reactions.

3. Studies involving human participants.

4. Studies reporting relevant genetic variations and medication outcomes.

5. Articles published in English.

6. Studies with accessible full-text information or sufficient outcome data.

4.5 Exclusion Criteria

1. Duplicate publications.

2. Studies unrelated to pharmacogenomics.

3. Studies without relevant drug safety outcomes.

4. Animal-only studies.

5. Editorials, opinion articles and unrelated commentaries.

6. Articles without sufficient methodological information.

4.6 Data Extraction

The following information will be collected from eligible studies:

- Author and publication year.

- Country of study.

- Study design.

- Number of participants.

- Gene and genetic variant investigated.

- Medication involved.

- Type of adverse drug reaction.

- Clinical outcomes.

- Evidence supporting pharmacogenomic-guided treatment.

4.7 Data Analysis

The findings will be summarized using descriptive tables and narrative synthesis.

A meta-analysis will only be considered if sufficient clinically comparable studies with appropriate quantitative data are identified.

RESULTS

Note: This section must be completed after conducting the actual database search and screening. No findings or participant numbers should be invented.

DISCUSSION

Pharmacogenomics provides an opportunity to understand individual variations in medication response and improve drug safety.

Genetic polymorphisms affecting drug-metabolizing enzymes can result in altered drug concentrations and differences in therapeutic response.

For example, CYP2C19 loss-of-function variants may reduce clopidogrel activation, potentially affecting its antiplatelet efficacy. Similarly, HLA-B*15:02 is an important genetic marker associated with carbamazepine-induced severe cutaneous reactions.

Evidence from pharmacogenomic implementation studies suggests that genotype-guided prescribing can reduce clinically relevant medication-related toxicity in selected clinical settings.

However, successful implementation requires consideration of economic, ethical, technological and clinical factors.

In addition, population-specific genetic diversity is important when developing pharmacogenomic testing strategies, particularly in countries with diverse genetic backgrounds such as India.

7. LIMITATIONS

Potential limitations of this systematic review include:

1. Heterogeneity in study designs and clinical outcomes.

2. Differences in genetic testing methods.

3. Limited representation of certain populations.

4. Variability in definitions and reporting of adverse drug reactions.

5. Differences in pharmacogenomic implementation across healthcare systems.

CONCLUSION

Pharmacogenomics represents an important advancement in personalized medicine and clinical pharmacology. Genetic variations can influence drug metabolism, therapeutic effectiveness and susceptibility to adverse drug reactions.

Identifying clinically relevant gene–drug interactions may help healthcare professionals select safer medications and optimize treatment strategies.

Although pharmacogenomic testing has demonstrated benefits for selected medications, further research is required to improve accessibility, affordability and clinical implementation, particularly in resource-limited healthcare settings.

REFERENCES

1. Alagoz, O., Durham, D., & Kasirajan, K. (2020). The role of pharmacogenomics in precision medicine and personalized therapy. Clinical Pharmacology & Therapeutics, 108 (4), 620–627.
2. Alfirevic, A., & Pirmohamed, M. (2017). Genomics of adverse drug reactions. Trends in Pharmacological Sciences, 38 (11), 1003–1017.
3. Aminkeng, F., Ross, C. J. D., & Hayden, M. R. (2014). Pharmacogenomics and adverse drug reactions: translating genetic discoveries into clinical practice. Human Genetics, 133 (8), 907– 921.
4. Ashley, E. A. (2016). Towards precision medicine. Nature Reviews Genetics, 17 (9), 507–522.
5. Bahar, M. A., Setiawan, D., Hak, E., & Wilffert, B. (2017). Pharmacogenetics of drug-induced QT interval prolongation: an update. Drug Safety, 40 (2), 117–133
6. Bank, P. C. D., Caudle, K. E., Swen, J. J., Gammal, R. S., Whirl-Carrillo, M., Klein, T. E., & Guchelaar, H. J. (2018). Comparison of the guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. Clinical Pharmacology & Therapeutics, 103 (4), 599–618.
7. 7.Chen, C. H., & Chen, Y. T. (2020). Pharmacogenomics of drug hypersensitivity: from bench to bedside. Pharmacogenomics, 21 (4), 221–233.
8. 8.Desta, Z., Gammal, R. S., Gong, L., Whirl-Carrillo, M., Gaur, A. H., Sukasem, C., ... & Caudle, K. E. (2019). Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2B6 and efavirenz dosing. Clinical Pharmacology & Therapeutics, 106 (4), 726–733.
9. 9.Caudle, K. E., Klein, T. E., Hoffman, J. M., Muller, D. J., Whirl-Carrillo, M., Gong, L., ... & Relling, M. V. (2017). Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline. Clinical Pharmacology & Therapeutics, 102 (3), 465–473.
10. Desta, Z., Gammal, R. S., Gong, L., Whirl-Carrillo, M., Gaur, A. H., Sukasem, C., ... & Caudle, K. E. (2019). Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2B6 and efavirenz dosing. Clinical Pharmacology & Therapeutics, 106 (4), 726–733.